EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib

Juliann Chmielecki, M. Catherine Pietanza, Dana Aftab, Ronglai Shen, Zhiguo Zhao, Xi Chen, Katherine Hutchinson, Agnes Viale, Mark G. Kris, Thomas Stout, Vincent Miller, Naiyer Rizvi, William Pao

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Introduction: EGFR-mutant lung cancers are sensitive to EGFR tyrosine kinase inhibitors (TKIs). Unfortunately, they develop resistance, often due to acquisition of a second-site mutation (T790M). Current EGFR TKIs select for T790M in preclinical models of acquired resistance. We explored whether all EGFR TKIs similarly select for the T790M mutation using data from early clinical trials and established in vitro models of acquired resistance. Methods: We analyzed the clinical characteristics of eight patients with metastatic EGFR-mutant lung adenocarcinoma who were treated first-line with XL647 and then progressed. XL647 is an ATP-competitive inhibitor of EGFR, HER2, KDR, and EPHB4. Additional molecular preclinical studies were performed to characterize resistance. Results: Four patients displayed confirmed partial responses (PRs), three patients had unconfirmed PRs, and one patient displayed stable disease. Only one of five patients' tumor samples available for analysis after disease progression harbored the T790M mutation. Eight patients subsequently received erlotinib, with (n = 3) or without (n = 5) chemotherapy. Three of five patients treated with single-agent erlotinib derived additional benefit, staying on drug up to 9 months. EGFR-mutant PC-9 cells with acquired resistance to XL647 did not harbor the T790M mutation, displayed a distinct mRNA profile from PC-9 cells with T790M-mediated resistance, and were moderately sensitive to erlotinib in growth inhibition assays. Crystal structure analyses of XL647/EGFR T790M did not reveal a different binding mode from that of erlotinib. Conclusions: The findings of this exploratory study suggest that different EGFR TKIs may select for distinct mechanisms of resistance. These results raise the possibility that different EGFR TKIs could be sequentially used to improve outcomes in patients with EGFR-mutant lung cancer. Further work investigating this hypothesis is warranted.

Original languageEnglish (US)
Pages (from-to)434-442
Number of pages9
JournalJournal of Thoracic Oncology
Volume7
Issue number2
DOIs
StatePublished - Feb 2012

Keywords

  • Acquired resistance
  • Afatinib
  • EGFR mutations
  • EGFR tyrosine kinase inhibitors
  • Erlotinib
  • Gefitinib
  • Non-small cell lung cancer
  • XL647

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib'. Together they form a unique fingerprint.

  • Cite this

    Chmielecki, J., Pietanza, M. C., Aftab, D., Shen, R., Zhao, Z., Chen, X., Hutchinson, K., Viale, A., Kris, M. G., Stout, T., Miller, V., Rizvi, N., & Pao, W. (2012). EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. Journal of Thoracic Oncology, 7(2), 434-442. https://doi.org/10.1097/JTO.0b013e31823c5aee